Global Assessment Puts Long COVID Rate at Six Percent
About 6% of people with symptomatic COVID-19 develop long COVID, according to an August 2026 global assessment by the World Health Organization. Among those affected, approximately 15% continue to experience symptoms 12 months later. “We now better know that there is no single cause for Long COVID,” says Majd Alsoubani, MD, MPH, an infectious disease physician at Tufts Medical Center. “It’s likely caused by several biological factors in different people.”
The condition, formally known as post-COVID-19 condition or PCC, encompasses more than 200 reported symptoms. Researchers have linked persistent health issues to multiple overlapping mechanisms, including chronic inflammation, vascular changes, and nervous system dysfunction. While anyone who has contracted the virus can develop the condition, the Centers for Disease Control and Prevention notes that risk is higher among Hispanic and Latino individuals, people who experienced severe initial illness requiring hospitalization, individuals with underlying health conditions, and those who did not receive a COVID-19 vaccine.
Persistent Inflammation and Systemic Physical Symptoms
An April 2024 study published in Nature Immunology found that individuals with long COVID exhibit elevated inflammation markers that persist long past the initial infection. While acute inflammation normally settles as a patient recovers from a viral attack, chronic inflammation can maintain symptoms such as brain fog, headaches, dizziness, and shortness of breath for weeks or months.
A February 2025 meta-analysis published in the peer-reviewed journal BMC Medicine, drawing on data from more than 3 million participants, revealed that individuals with long COVID face a significantly higher likelihood of chest pain, heart palpitations, and elevated blood pressure compared to people who were never infected. Furthermore, a collaborative study involving the Winchester Center for Lung Disease, the Yale Pulmonary Vascular Disease Program, and Brigham and Women’s Hospital demonstrated that some recovered patients retain a marked reduction in peak oxygen consumption even when standard heart and lung tests appear normal.
Cognitive Impairment and Post-Exertional Malaise
Neurological and cognitive impacts affect a substantial portion of patients. A 2026 review of 47 studies encompassing over 25,000 long COVID patients estimated that roughly 30% experience brain fog, while 25% show measurable cognitive impairment, according to the Yale School of Medicine. A 2026 clinical trial published in JAMA Network Open demonstrated that an individualized, goal-oriented cognitive treatment program can improve everyday functional goals for affected individuals.
Severe fatigue affects between 30% and 65% of patients, as noted in 2025 research published in Viruses. This fatigue frequently accompanies post-exertional malaise, a condition characterized by a severe drop in physical and mental energy following minor exertion. According to the Journal of Clinical Medicine, this crash typically manifests 12 to 48 hours after activity. A 2026 brain imaging study published in eBioMedicine identified changes in the brain’s dopamine system among long COVID patients, offering a potential biological mechanism for both fatigue and cognitive symptoms.
Vaccination Impact and Ongoing Clinical Trials
Preventing reinfection remains the most effective defense against developing post-COVID conditions. Recent studies published in 2025 showed that vaccinated people have roughly a 20% to 30% lower risk of long COVID compared with unvaccinated people. Dr. Alsoubani notes that vaccinated individuals possess roughly a 20% to 30% lower risk of developing long COVID compared to unvaccinated populations.
For the 2026–2027 season, the CDC recommends an updated COVID-19 vaccine for all adults ages 18 and older. Treatment remains focused on individualized symptom management, such as activity pacing for post-exertional malaise. Meanwhile, the NIH RECOVER Initiative is evaluating several targeted therapies in clinical trials, including baricitinib, semaglutide, low-dose naltrexone, and stellate ganglion nerve blocks, to address the diverse biological drivers of the condition.
Worth a look